Colchicine reduced adverse cardiovascular events by 31% and recurrent MI by 55% but did not affect mortality and increased GI side effects (OR 2.11).
Does colchicine reduce adverse cardiovascular outcomes in individuals who have experienced a myocardial infarction?
In post-MI patients, colchicine significantly reduces the risk of adverse cardiovascular outcomes and recurrent MI, but is associated with an increased risk of gastrointestinal side effects.
Absolute Event Rate: 0% vs 0%
Abstract Introduction Myocardial infarction (MI) is still one of the world's major causes of morbidity and mortality.Colchicine, a medication known for its anti-inflammatory properties and commonly prescribed to reduce post-myocardial infarction (MI) inflammation and related negative cardiovascular outcomes. Our systematic review and meta-analysis seeks to thoroughly assess the safety and effectiveness of colchicine in individuals who have experienced an MI. Purpose Our study aimed to show colchicine in diminishing negative cardiovascular events, such as recurrent myocardial infarction (MI), stroke, and cardiac arrest, as well as its influence on overall mortality. Furthermore, the study sought to investigate the anti-inflammatory properties of colchicine by examining alterations in high-sensitivity C-reactive protein (hs-CRP) levels and to assess its safety profile, especially concerning gastrointestinal (GI) side effects. Method A comprehensive literature was searched across key databases such as PubMed, Embase, and the Cochrane Library assessing colchicine in individuals with MI or those at elevated risk for cardiovascular events. . Outcomes were evaluated by random-effects models and heterogeneity was examined using the I² statistic. Random-effects models used to determine hazard ratios (HRs), odds ratios (OR) along with 95% confidence intervals (CIs). p-value 0.05 considered significant. Results A total of 14,199 individuals participated, with 7,074 receiving colchicine and 7,125 given a placebo. Colchicine showed a notable decrease in the adverse cardiovascular outcomes when compared to the placebo,an odds ratio (OR) of 0.69 95% CI: 0.53, 0.91, p = 0.007, signifying a 31% reduction. The occurrence of recurrent myocardial infarction (MI) was also significantly reduced in the colchicine group (OR = 0.45 95% CI: 0.30, 0.67, p = 0.0001), indicating a 55% decrease. Nevertheless, colchicine had no significant impact on overall mortality (OR = 0.93 95% CI: 0.78, 1.12, p = 0.45), stroke occurrence (OR = 0.64 95% CI: 0.26, 1.59, p = 0.33), or the incidence of cardiac arrest (OR = 0.80 95% CI: 0.33, 1.96, p = 0.63). A trend indicating lower hs-CRP levels was noted (mean difference = -0.87 95% CI: -1.80, 0.06, p = 0.07), implying possible anti-inflammatory effects. Colchicine was linked to a significantly risk of gastrointestinal adverse events (OR = 2.11 95% CI: 1.20, 3.74, p = 0.01). Conclusion Colchicine is effective in lowering the incidence of cardiovascular events and recurrent myocardial infarction, and it may offer anti-inflammatory advantages. It does not have a considerable effect on overall mortality, stroke incidents, or cardiac arrest and is linked to an increased risk of gastrointestinal side effects.Additional studies are required to enhance its role in managing cardiovascular diseases.
Warsi et al. (Sat,) reported a other. Colchicine reduced adverse cardiovascular events by 31% and recurrent MI by 55% but did not affect mortality and increased GI side effects (OR 2.11).